Zuplenz (ondansetron oral dispersible film) / tesa, Vestiq Pharma, SELLAS Life Sciences, Norgine, Italfarmaco - LARVOL DELTA

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers (clinicaltrials.gov) - P1 | N=36 | Terminated | Sponsor: National Cancer Institute (NCI) | Completed ➔ Terminated; Site plans to become a site for a multicenter study of this therapy

IO biomarker • Trial termination • Gene Therapies • Lung Cancer • Oncology • Solid Tumor

Evaluation of the Safety, Tolerability, and Efficacy of Preoperative Ondansetron Orally Dissolving Film for Prophylactic Antiemesis in Patients Undergoing Pulmonary Surgery (ChiCTR) - P4 | N=306 | Not yet recruiting | Sponsor: Peking University Cancer Hospital; Peking University Cancer Hospital

New P4 trial

Efficacy and safety of ondansetron oral dissolving membrane combined with Huoxiang Zhengqi oral liquid in the prevention of delayed nausea and vomiting caused by hyperemetic chemotherapy: a randomized controlled clinical trial (ChiCTR) - P2 | N=84 | Not yet recruiting | Sponsor: Affiliated Hospital of Southwest Medical University; Affiliated Hospital of Southwest Medical University

New P2 trial • Solid Tumor

Evaluation of the efficacy and safety of ondansetron oral film in the prevention of postoperative nausea and vomiting after primary total joint arthroplasty (ChiCTR) - P=N/A | N=330 | Not yet recruiting | Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University

New trial • Orthopedics • Rheumatology

Development of a Hydrocortisone Orodispersible Thin Film Containing Its Succinate Prodrug. (PubMed, Pharmaceuticals (Basel)) - "The ODF formulated with the water-soluble hydrocortisone prodrug HMS allows accurate drug level to be achieved, thus opening up new opportunities for use in pediatric patients."

Journal • Endocrine Disorders • Pediatrics

Granisetron Versus Ondansetron for Nausea and Vomiting in Pediatric Age Group (clinicaltrials.gov) - P=N/A | N=160 | Completed | Sponsor: Ain Shams University

New trial • Gastroenterology • Gastrointestinal Disorder • Pediatrics

Transversus Abdominis Plane Block in Microsurgical Breast Recon w/Abdominal Free Flap in Breast CA (clinicaltrials.gov) - P3; N=120; Completed; Sponsor: Stanford University; Recruiting ➔ Completed; Trial completion date: Mar 2020 ➔ Jun 2021

Trial completion • Trial completion date

LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov) - P2; N=150; Active, not recruiting; Sponsor: British Columbia Cancer Agency; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD20

Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia (clinicaltrials.gov) - P3; N=8; Completed; Sponsor: University of Colorado, Denver; N=85 ➔ 8

Enrollment change • CNS Disorders • Psychiatry • Schizophrenia

Three-way Crossover Study Comparing Ondansetron ODFS Administered With and Without Water to Zofran ODT Without Water (clinicaltrials.gov) - P1; N=18; Completed; Sponsor: Aquestive Therapeutics; Phase classification: P3 ➔ P1

Clinical • Phase classification

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - P2; N=37; Completed; Sponsor: M.D. Anderson Cancer Center; Recruiting ➔ Completed; N=91 ➔ 37; Trial completion date: Dec 2020 ➔ Jul 2020; Trial primary completion date: Dec 2020 ➔ Jul 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Oncology • Sarcoma • Solid Tumor

Rolapitant Hydrochloride in Preventing Nausea/Vomiting in Patients With Sarcoma Receiving Chemotherapy (clinicaltrials.gov) - P2; N=37; Terminated; Sponsor: M.D. Anderson Cancer Center; Completed ➔ Terminated; Terminated per PI's request

Clinical • Trial termination • Oncology • Sarcoma • Solid Tumor

Crossover Study Comparing Ondansetron Orally Dissolving Film Strip (ODFS) With Zofran Orally Disintegrating Tablets (clinicaltrials.gov) - P1/2; N=48; Completed; Sponsor: MonoSol Rx; Phase classification: P3 ➔ P1/2

Clinical • Phase classification

Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - P4; N=70; Recruiting; Sponsor: University of Texas Southwestern Medical Center; Trial primary completion date: Jan 2017 ➔ Feb 2018

Trial primary completion date • Biosimilar • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders

LYTPET: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment (clinicaltrials.gov) - P2; N=150; Active, not recruiting; Sponsor: British Columbia Cancer Agency; Trial completion date: Dec 2018 ➔ Dec 2020; Trial primary completion date: Dec 2018 ➔ Dec 2020

Clinical • Trial completion date • Trial primary completion date

Ondansetron for Bipolar Disorder and Alcohol Use Disorders (clinicaltrials.gov) - P4; N=70; Active, not recruiting; Sponsor: University of Texas Southwestern Medical Center; Completed ➔ Active, not recruiting; Trial completion date: Mar 2018 ➔ Oct 2019; Trial primary completion date: Mar 2018 ➔ Oct 2019

Enrollment closed • Trial completion date • Trial primary completion date